Edition:
India

Zoetis Inc (ZTS.N)

ZTS.N on New York Stock Exchange

55.57USD
1:32am IST
Change (% chg)

$0.45 (+0.82%)
Prev Close
$55.12
Open
$55.15
Day's High
$55.68
Day's Low
$55.08
Volume
841,181
Avg. Vol
867,951
52-wk High
$56.50
52-wk Low
$45.28

ZTS.N

Chart for ZTS.N

About

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock)... (more)

Overall

Beta: 1.03
Market Cap(Mil.): $27,098.53
Shares Outstanding(Mil.): 491.63
Dividend: 0.10
Yield (%): 0.76

Financials

  ZTS.N Industry Sector
P/E (TTM): 33.45 29.34 30.35
EPS (TTM): 1.65 -- --
ROI: 12.97 13.84 13.36
ROE: 64.27 14.77 14.50

BRIEF-Zoetis gets European Commission marketing authorization for Cytopoint

* Zoetis receives european commission marketing authorization for Cytopoint® (lokivetmab) Source text for Eikon: Further company coverage:

2:27am IST

BRIEF-Zoetis to acquire Nexvet for US$6.72 in Cash Per Share

* Zoetis to acquire Nexvet Biopharma, an innovator in monoclonal antibody therapies for companion animals

13 Apr 2017

BRIEF-Zoetis CEO's 2016 total compensation was $9.5 million

* CEO Juan Ramón Alaix's 2016 total compensation was $9.5 million versus $8.7 million in 2015 Source text:(http://bit.ly/2nRVXcH) Further company coverage:

31 Mar 2017

BRIEF-Zoetis reports Q4 EPS $0.31

* Q4 earnings per share view $0.45 -- Thomson Reuters I/B/E/S

16 Feb 2017

BRIEF-Zoetis receives European commission approval for stronghold plus

* Zoetis receives European commission approval for stronghold plus Source text for Eikon: Further company coverage:

16 Feb 2017

BRIEF-Pershing Square dissolves sole share stake in Zoetis Inc

* Pershing Square Capital Management dissolves sole share stake in Zoetis Inc - SEC filing

15 Feb 2017

BRIEF-Zoetis sees Q3 adjusted EPS $0.52

* Zoetis inc- increases diluted eps to $1.66 - $1.75 on a reported basis, or $1.91 - $1.96 on an adjusted basis for full year 2016

02 Nov 2016

More From Around the Web

Competitors

  Price Chg
Merck & Co., Inc. (MRK.N) $62.70 +0.40
Bayer AG (BAYGn.DE) €108.05 -0.40
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €85.65 +0.56
Eli Lilly and Co (LLY.N) $80.96 -0.24

Earnings vs. Estimates